Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

[Brain-enhancement: anthropological, sociological and legal issues].

Larrieu P.

J Int Bioethique Ethique Sci. 2018 Dec 18;29(3):71-91. doi: 10.3917/jibes.293.0071. French.

PMID:
30767462
2.

Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues.

Théate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, Van den Eynde BJ.

Cancer Immunol Res. 2015 Feb;3(2):161-72. doi: 10.1158/2326-6066.CIR-14-0137. Epub 2014 Sep 30.

3.

A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming.

Michaux A, Larrieu P, Stroobant V, Fonteneau JF, Jotereau F, Van den Eynde BJ, Moreau-Aubry A, Vigneron N.

J Immunol. 2014 Feb 15;192(4):1962-71. doi: 10.4049/jimmunol.1302032. Epub 2014 Jan 22.

4.

Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A.

Dolušić E, Larrieu P, Meinguet C, Colette D, Rives A, Blanc S, Ferain T, Pilotte L, Stroobant V, Wouters J, Van den Eynde B, Masereel B, Delfourne E, Frédérick R.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):47-54. doi: 10.1016/j.bmcl.2012.11.036. Epub 2012 Nov 22.

PMID:
23218716
5.

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frédérick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2497-502. doi: 10.1073/pnas.1113873109. Epub 2012 Jan 30.

6.

HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.

Chauvin JM, Larrieu P, Sarrabayrouse G, Prévost-Blondel A, Lengagne R, Desfrançois J, Labarrière N, Jotereau F.

J Immunol. 2012 Mar 1;188(5):2102-10. doi: 10.4049/jimmunol.1101807. Epub 2012 Jan 30.

7.

Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.

Dolusić E, Larrieu P, Moineaux L, Stroobant V, Pilotte L, Colau D, Pochet L, Van den Eynde B, Masereel B, Wouters J, Frédérick R.

J Med Chem. 2011 Aug 11;54(15):5320-34. doi: 10.1021/jm2006782. Epub 2011 Jul 18.

PMID:
21726069
8.

Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.

Dolušić E, Larrieu P, Blanc S, Sapunaric F, Pouyez J, Moineaux L, Colette D, Stroobant V, Pilotte L, Colau D, Ferain T, Fraser G, Galleni M, Frère JM, Masereel B, Van den Eynde B, Wouters J, Frédérick R.

Eur J Med Chem. 2011 Jul;46(7):3058-65. doi: 10.1016/j.ejmech.2011.02.049. Epub 2011 Feb 26.

9.

Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.

Dolušić E, Larrieu P, Blanc S, Sapunaric F, Norberg B, Moineaux L, Colette D, Stroobant V, Pilotte L, Colau D, Ferain T, Fraser G, Galleni M, Frère JM, Masereel B, Van den Eynde B, Wouters J, Frédérick R.

Bioorg Med Chem. 2011 Feb 15;19(4):1550-61. doi: 10.1016/j.bmc.2010.12.032. Epub 2010 Dec 16. Erratum in: Bioorg Med Chem. 2011 May 1;19(9):3029. Galeni, Moreno [corrected to Galleni, Moreno].

10.

Folding of matrix metalloproteinase-2 prevents endogenous generation of MHC class-I restricted epitope.

Renaud V, Godefroy E, Larrieu P, Fleury F, Jotereau F, Guilloux Y.

PLoS One. 2010 Jul 30;5(7):e11894. doi: 10.1371/journal.pone.0011894.

11.

Rational design of indoleamine 2,3-dioxygenase inhibitors.

Röhrig UF, Awad L, Grosdidier A, Larrieu P, Stroobant V, Colau D, Cerundolo V, Simpson AJ, Vogel P, Van den Eynde BJ, Zoete V, Michielin O.

J Med Chem. 2010 Feb 11;53(3):1172-89. doi: 10.1021/jm9014718.

PMID:
20055453
12.

A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.

Larrieu P, Renaud V, Godet Y, Jotereau F, Fonteneau JF.

Cancer Immunol Immunother. 2008 May;57(5):745-52. Epub 2007 Dec 21.

PMID:
18097665
13.

Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting.

Srinivas O, Larrieu P, Duverger E, Boccaccio C, Bousser MT, Monsigny M, Fonteneau JF, Jotereau F, Roche AC.

Bioconjug Chem. 2007 Sep-Oct;18(5):1547-54. Epub 2007 Jun 29.

PMID:
17602511
14.

A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.

Larrieu P, Ouisse LH, Guilloux Y, Jotereau F, Fonteneau JF.

Cancer Immunol Immunother. 2007 Oct;56(10):1565-75. Epub 2007 Feb 23.

PMID:
17318652
15.

[Epidemiology of human hydatidosis in the Province of Río Negro, Argentina].

Larrieu PE, Lester R, Rodríguez Jauregui J, Odriozzola M, Medina M, Aguero AM.

Acta Gastroenterol Latinoam. 1986;16(2):93-108. Spanish.

PMID:
3577624

Supplemental Content

Loading ...
Support Center